Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
NCT06607003
Recruiting
Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020. Researchers are working to develop vaccines and treatments for this disease. Objective: To learn how malaria develops in people; how the body's immune system reacts to malaria; and how malaria spreads from people to mosquitoes. Eligibility: Healthy people in the Washington DC area, aged 18 to 54 years. They cannot l... Read More
Gender:
ALL
Ages:
Between 18 years and 54 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Malaria
Register for Updates
Assessing the Effect of Computer-based Auditory Training on Adult Cochlear Implant Speech and Quality-of-life Outcomes
NCT06607146
Recruiting
The purpose of this study is to compare the effectiveness of a free computer-based auditory training program, Sound Success (Advanced Bionics, Valencia, CA), with the current standard of care of patient-directed auditory training in improving common measures of speech recognition and cochlear implant (CI) specific quality-of-life in new adult CI recipients in their first year post-activation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cochlear Implants, Bilateral Sensorineural Hearing Loss
Register for Updates
Evaluation of an Online Prostate Cancer Screening Decision Aid
NCT06610474
Recruiting
The goal of this clinical trial is to learn if the online, simulated human "Talk to Nathan About Prostate Cancer Screening" decision aid (https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html) is effective in helping patients decide about prostate cancer screening. The main questions it aims to answer are: * Is using the "Talk to Nathan About Prostate Cancer Screening" decision aid effective in improving knowledge, overcoming health literacy barriers, and resolving decisional conflict c... Read More
Gender:
MALE
Ages:
Between 55 years and 69 years
Trial Updated:
07/31/2025
Locations: East Northport Medical Care, East Northport, New York +1 locations
Conditions: Prostate Cancer
Register for Updates
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
NCT06617858
Recruiting
To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer
Register for Updates
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060
Recruiting
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will b... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/31/2025
Locations: MD First Research - Chandler, Chandler, Arizona +15 locations
Conditions: Episodic Migraine, Chronic Migraine
Register for Updates
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
NCT06625515
Recruiting
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-559 in patients with advanced solid tumors and molecularly defined cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Colorado Cancer Center - Anschutz Medical Campus,, Aurora, Colorado +4 locations
Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Register for Updates
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
NCT06664879
Recruiting
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/31/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: AML
Register for Updates
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
NCT06676046
Recruiting
Background: The right amount of fats in the blood (cholesterol and triglycerides) are a key part of a healthy organism. Too much or too little of these fats may manifest as diseases (dyslipidemia). There are many causes for these abnormalities, but some are genetically determined and we would like to better understand the progression of these conditions over time. Objective: This natural history study aims to learn more about dyslipidemias; how they change over time; and how they respond to t... Read More
Gender:
ALL
Ages:
Between 10 years and 90 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dyslipidemia, Atherosclerosis
Register for Updates
Trajectories of Change in Tourette Syndrome
NCT06679790
Recruiting
This K23 Career Development Award is designed to provide the training needed for the PI to achieve her long-term career goal of conducting independent, programmatic intervention research in developmental populations. The training will emphasize gaining expertise in higher-intensity, multi-method, within-subject data collection and analysis. This award builds on the PI's emerging experience in tic disorders and pediatric behavioral interventions, and her ability to quickly learn and apply advance... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Tourette Syndrome, Tic Disorders
Register for Updates
Opioid Use and Criminal Justice: Intervening to Improve the Outcomes of Women
NCT06682364
Recruiting
Opioid-related overdose deaths and incarceration rates have skyrocketed and have disproportionately affected women. Despite having a higher burden of substance use disorders and HIV/AIDS than criminal justice-involved (CJI) men, CJI women are less likely to have access to substance use and HIV treatment. The planned research aims to improve how women in the criminal justice system connect to and stay in drug treatment. This will be done by creating and putting into practice a well-researched pro... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Recovery, Advocacy, Service, and Empowerment (RASE), Harrisburg, Pennsylvania
Conditions: Opioid Use Disorder
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793
Recruiting
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +8 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Register for Updates
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847
Recruiting
The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC, Sun City, Arizona +122 locations
Conditions: Primary Sjogrens Disease
Register for Updates